as 05-20-2024 11:33am EST
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
Founded: | 2011 | Country: | United States |
Employees: | 32 | City: | BOSTON |
Market Cap: | 102.8M | IPO Year: | 2021 |
Target Price: | $10.00 | AVG Volume (30 days): | 58.1K |
Analyst Decision: | Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -8.63 | EPS Growth: | N/A |
52 Week Low/High: | $2.96 - $24.39 | Next Earning Date: | 05-15-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Chudnovsky Yekaterina | ELTX | Director10% Owner | Dec 22 '23 | Buy | $5.81 | 1,213,000 | $7,047,530.00 | 1,915,639 | SEC Form 4 |
ELTX Breaking Stock News: Dive into ELTX Ticker-Specific Updates for Smart Investing
Power Technology
4 days ago
GlobeNewswire
5 days ago
GlobeNewswire
25 days ago
Simply Wall St.
a month ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago